Promoting cancer management by liquid biopsy
KEY DATA
Laboratory of Rare Human Circulating Cells (LCCRH)
google-site-verification: google32a0b6fdb705276e.html
A clinical cancer research laboratory
Promotion of the use of a non-invasive method of cancer diagnosis and monitoring. The liquid biopsy is a blood test that provides key information for personalized medicine: early detection, identification of therapeutic targets, progression, treatment efficacy, minimal residual disease of cancer.
Our story
Creation of the laboratory (European FEDER and region funds)
Invention of the term Liquid Biopsy with Professor Klaus Pantel
Gallet and Breton Prize of the National Academy of Medicine
Culture of the first permanant CTC lines from metastatic colon cancer patient
Most cited article from the AACRย https://www./articles/nrc3820
First evidence that CTCs express PD-L1
EPIDROPย patent
1st demonstration of the clinical utility of CTCs (STIC study)
Liquid biopsy as a key discovery during the last 20 years
Listed in the 10 most cited article on Liquid Biopsy in the world ย https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006671/
Relocation of the laboratory to new premises
News
Les biopsies liquides: une vraie rรฉvolution !
Jeudi soir, lors de la remise des prix de la 15รจmeย Biennale de Cancรฉrologie, le docteur Catherine Alix- Panabiรจres a reรงu le prix Savchuck de la fondation รฉponyme pour ses travaux sur les ยซย biopsies liquidesย ยป qui sont certainement appelรฉes ร permettre des avancรฉes considรฉrables dans le diagnostic et le traitement des cancers.
ยฉ 2023-2024 LCCRH . All rights reserved. The laboratory expresses his gratitude to all of the patients who put their confidence in them for cancer research.